Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
about
Targeting Src family kinases in anti-cancer therapies: turning promise into triumphInhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.SRC: a century of science brought to the clinic.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancerTargeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studiesTrastuzumab has preferential activity against breast cancers driven by HER2 homodimers.Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinoma.Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumoursNew insights on the role of hormonal therapy in ovarian cancerAn essential role of p27 downregulation in fenvalerate-induced cell growth in human uterine leiomyoma and smooth muscle cells.Mouse mammary tumor virus suppresses apoptosis of mammary epithelial cells through ITAM-mediated signaling.Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivoInhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells.The dual kinase complex FAK-Src as a promising therapeutic target in cancerTargeting p27Kip1 protein: its relevance in the therapy of human cancer.Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.Advances in mechanisms of resistance to aromatase inhibitors.Emerging strategies to overcome resistance to endocrine therapy for breast cancer.Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.
P2860
Q27025646-D604BE9C-D3B8-45C2-9192-019BBB201C02Q30419413-0A4DCD51-9066-45BB-BCBF-156F0A967717Q34041298-62BB782D-7EB2-48BB-AB18-EB012E1C3152Q34121339-84B0F414-E3EF-484E-B4B9-36A344FD3C07Q34472383-CF4B0699-B01F-48E9-9F72-9861BB34101DQ35145443-0B1044E9-AC1F-4534-AA72-49FDB1FC2766Q35539318-5B78FCAE-7C6F-4310-8817-64D9459BBA6FQ35566231-33C9C8D9-4495-473C-91AA-7DA81E984DDBQ35569694-54EFC20A-DF56-47D8-B017-75224130CB69Q35919052-1ACFA44A-7F08-46CF-82B6-C22834163830Q35998482-1B5F6609-8D5D-4E46-B365-A0D43E6D8778Q36001247-2F60F1F7-1AED-40A4-9267-77328423D635Q36312422-601407E4-BB3F-469A-99C6-6AA689DE0FC1Q36414488-3F2B3844-DD4F-4C49-8296-D32EF0B03140Q36974565-937DCE31-CDC3-4238-9B96-C32BA9F85C18Q37626072-895C5BD9-F2FB-47B9-B1D4-1CFB511424ADQ37771259-65ED85E0-8B32-4DF3-8472-2113DC4117E8Q37847584-3F0CEAF0-C3BC-4ABA-8832-61135C3B1986Q37992693-006D47AF-4A0C-4B89-946F-C5813B5F27E9Q38190106-80012131-68AB-4E8A-896C-A969C348C566Q38221463-DB351B91-EAA7-42C9-8B6D-C0ECE05355B7Q38784119-DD1B29C3-46B4-4F73-A655-64CD5293B118Q39160945-B2B9519D-3BCE-48C4-8DEC-E37FB0BA011CQ39555328-2E25C2ED-0680-4E3A-883C-F44A6F7B81FAQ39674037-F826ED0F-8D9E-4411-B3E7-B4178D1AAF01Q39720714-D67E992F-7CB8-4AE9-9EA3-77BD4F8002E5Q52619388-6D2CF496-5B8C-4B7A-B59A-121B36E3CCDBQ54610139-64B4FC20-D08D-44DC-9DD2-05CB8A4508E1
P2860
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Combined Src and aromatase inh ...... d in AZD0530-resistant tumors.
@en
Combined Src and aromatase inh ...... d in AZD0530-resistant tumors.
@nl
type
label
Combined Src and aromatase inh ...... d in AZD0530-resistant tumors.
@en
Combined Src and aromatase inh ...... d in AZD0530-resistant tumors.
@nl
prefLabel
Combined Src and aromatase inh ...... d in AZD0530-resistant tumors.
@en
Combined Src and aromatase inh ...... d in AZD0530-resistant tumors.
@nl
P2093
P1476
Combined Src and aromatase inh ...... d in AZD0530-resistant tumors.
@en
P2093
Ana Gonzalez-Angulo
Bryan Hennessy
Chen-Keat Tan
Gordon B Mills
Joyce M Slingerland
Merce Jorda
Natalia Guggisberg
P304
P356
10.1158/1078-0432.CCR-08-3127
P407
P577
2009-05-01T00:00:00Z